Linagliptin/Metformin Duo Tablet 2.5/500mg
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Daewoo Pharmaceutical Co., Ltd.
MFDS item code 201905853 · Approved 2019.08.19
This product's status changed to Expired on 2024.08.19. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in adults with type 2 diabetes
This medication is used as an adjunctive therapy to improve blood glucose control in adults with type 2 diabetes, alongside diet and exercise. It can be used in patients who have difficulty controlling blood glucose with monotherapy when starting diabetes medication. Additionally, it can replace the combination therapy of linagliptin and metformin, or it can be used with insulin when combination therapy with insulin and metformin is insufficient for adequate blood glucose control. Furthermore, when blood glucose control is inadequate even with the maximum dose of metformin and empagliflozin, it can be used in combination with empagliflozin to enhance blood glucose control. This medication helps improve blood glucose control in various combination therapy scenarios.
The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each ingredient: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medication is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should initially take the same doses of linagliptin and metformin they had been taking. 3. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medication should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medication is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Cautious Administration). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medication. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustments. As the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin. (See Precautions for Use, 1. Do not administer to the following patients.)
This medication can cause a serious metabolic complication called lactic acidosis, so it should not be administered to patients at high risk for lactic acidosis. This medication contains linagliptin and metformin, so it should not be used in patients who are allergic to these ingredients or who have certain conditions (e.g., type 1 diabetes, lactic acidosis, severe renal impairment, severe liver dysfunction). Patients with impaired renal function should undergo renal function tests before using this medication, and it should not be administered if renal function is below a certain level. When using this medication, hypoglycemic symptoms may occur, especially when taken with other glucose-lowering agents such as sulfonylureas or insulin, so caution is advised. This medication should be discontinued in acute conditions such as acute heart failure, acute myocardial infarction, or severe infections, and can be resumed once the condition stabilizes. If skin adverse reactions such as acute pancreatitis or bullous pemphigoid occur, stop taking this medication immediately and consult healthcare providers. This medication may lower vitamin B12 levels, so it is advisable to regularly check for vitamin B12 deficiency if taken for a long time. It is not safe for women who are pregnant or may be pregnant, or for nursing mothers to use this medication. Elderly patients may commonly have reduced renal function, so renal function should be regularly monitored, and the dosage adjusted when administering this medication. This medication may interact with various drugs, so inform the doctor or pharmacist if taking other medications. Avoid excessive alcohol consumption while taking this medication, and immediately report to healthcare providers if severe dehydration, vomiting, diarrhea, or similar symptoms occur, and consider stopping the medication. This medication can be taken without regard to meals, but for reducing gastrointestinal discomfort, it is recommended to take it during or after meals. There is a risk of lactic acidosis from overdose, so it is essential to adhere strictly to the prescribed dosage, and to visit a hospital immediately if any unusual symptoms occur.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a tightly closed container. It is best to store it at room temperature between 1 to 30 degrees Celsius.
Bright yellow, biconvex oval film-coated tablet
10 tablets/PTP [(10 tablets/PTP packaging x 6)], 6 PTPs/box
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Daewoo Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.